Clinical PromiseZervimesine appears applicable across multiple fronts, demonstrating clinical promise as Cognition Therapeutics' lead candidate.
Market PotentialDementia with Lewy bodies could represent a blockbuster or near-blockbuster indication, with roughly $1B in peak annual sales for zervimesine in the U.S. alone.
Trial ResultsResults indicate the study met its primary endpoint of safety and tolerability, with data showing that DLB patients treated with CT1812 for six months experienced improvement in behavioral, functional, cognitive and movement measures compared to placebo.